A new study conducted by International Breast Cancer Intervention society termed IBIS-I have suggested that Tomoxifen can prove to be an effective drug against the breast cancer.
The study suggested that Tamoxifen intake five years among women can decrease the risk of breast cancer among high risk patients. The researchers said the breast cancer risk can be reduced to as high as 30 percent.
The study has also concluded that the protection offered by the Tamoxifen drug can last for as long as 16 years even after stopping the drug intake.
The trial-I study conducted by the International Breast Cancer Intervention studies was started in the year 1992 and has inspected over 7,150 patients who are at risk of getting affected by breast cancer.
The study which was published in The Lancet Oncology journal has also suggested that patients who are not on hormone replacement drugs shows a better 38 percent reduction in breast cancer diagnosis.
Dr Jack Cuzick, PhD from Queen Mary University in London in a statement released said, “With an additional 10 years of follow-up we have substantially larger differences which bodes well for the prospects that the prevention may even be longer than 20 years-potentially a lifetime.”
It is interesting to note that earlier there were reports which suggested that a regular and increase intake of Tamoxifen drug may lead to uterine cancer. So it seems that the regular chemotherapy combined with Tamoxifen may be affective but not Tamoxifen alone.